The “Harmony in Healthcare: The 2024 National Conference on Anti-Aging, Alternative Medicine, Aesthetic Medicine, and Wellness” (SMART) took place in Thailand from July 20th to 21st. This prestigious international conference is a leading platform for the exchange of advancements in medical technology, focusing on anti-aging, alternative medicine, aesthetic medicine, and overall wellness.
At this year’s conference, Wikkon introduced its latest innovation, the E300 Erectile Dysfunction Treatment Device. This new product attracted significant attention from both local and international industry experts, thanks to its advanced performance and innovative technology.
The E300 device represents a major advancement in the field of andrology. It utilizes low-intensity shock wave therapy (LI-ESWT) to promote penile revascularization and improve blood circulation in a non-invasive and painless manner. This approach offers a natural restoration of erectile function and represents a significant departure from traditional treatment methods. The device’s efficiency, safety, and user-friendly design were key highlights of the exhibition, drawing considerable interest from medical professionals.
During the conference, many attendees were intrigued by the E300’s innovative technology. Medical professionals engaged in discussions about the device’s efficacy, safety, and convenience, and praised it as a promising new treatment option for erectile dysfunction.
Our Thailand agent, a key partner in Southeast Asia, has been instrumental in bringing cutting-edge medical technology to the region. The successful conclusion of SMART has further strengthened our collaboration with Thailand’s medical community. Moving forward, we are committed to our mission of “scientific and technological innovation, serving health.” We will continue to develop high-quality medical products and collaborate with global partners to advance medical technology and contribute to global health.
We look forward to seeing the E300 benefit more patients in the future and to continuing our efforts to enhance care and health outcomes worldwide.
